1 World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241–68.
3 Frey B, Petignat P, Jaccot-Guillarmod M. Recommandations pour la prévention du cancer du col de l’utérus. Avis d’experts 2018 de la Société Suisse de Gynécologie et d’Obstétrique SSGO (in press).
4 Denny L, de Sanjose S, Mutebi M, Anderson BO, Kim J, Jeronimo J, et al. Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries. Lancet. 2017;389(10071):861–70.
5 Moscicki A-B, Darragh TM, Berry-Lawhorn JM, Roberts JM, Khan MJ, Boardman LA, et al. Screening for Anal Cancer in Women. J Low Genit Tract Dis. 2015;19(3, Suppl 1):27–42.
6 Beachler DC, Jenkins G, Safaeian M, Kreimer AR, Wentzensen N. Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis. J Infect Dis. 2016;213(9):1444–54.
7 Osborne SL, Tabrizi SN, Brotherton JML, Cornall AM, Wark JD, Wrede CD, et al.; VACCINE Study group. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine. 2015;33(1):201–8.
8 Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085–92.
9 Bosch FX, Robles C, Díaz M, Arbyn M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Oncology 2016 13:119–32.
10 Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al.; HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.
11 Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ 2014;349(oct28 1):g6192–2.
12 Castanon A, Landy R, Pesola F, Windridge P, Sasieni P. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study. Lancet Public Health. 2018;3(1):e34–43.
13 Office fédéral de la santé publique. Vaccination contre les HPV : recommandation de vaccination complémentaire pour les garçons et jeunes hommes âgés de 11 à 26 ans. Bulletin OFSP 2015;(10):141–9.
14 Anic GM, Lee JH, Villa LL, Lazcano-Ponce E, Gage C, José C Silva R, et al. Risk factors for incident condyloma in a multinational cohort of men: the HIM study. J Infect Dis. 2012;205(5):789–93.
15 Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst. 2013;105(7):469–74.
16 Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013;346(apr18 1):f2032–2.
17 Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401–11.
18 Office fédéral de la santé publique. La syphilis en Suisse, situation en 2016. Bulletin OFSP. 2017;43:21.
19 Lehtinen M, Söderlund-Strand A, Vänskä S, Luostarinen T, Eriksson T, Natunen K, et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I). Int J Cancer. 2018;142(5):949–58.
20 Kreimer AR, Chaturvedi AK. HPV-associated Oropharyngeal Cancers – Are They Preventable? Cancer Prev Res (Phila). 2011;4(9):1346–9.
21 CDC Centers for Disease Control and Prevention. number of HPV-attributable cancer cases per year.
https://www.cdc.gov/cancer/hpv/statistics/cases.htm. Zugang verifiziert am 30.8.2018
22 Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, et al.; Costa Rica HPV Vaccine Trial (CVT) Group. Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. J Natl Cancer Inst. 2015;108(1):djv302.
23 Pottie K, Greenaway C, Feightner J, Welch V, Swinkels H, Rashid M, et al.; coauthors of the Canadian Collaboration for Immigrant and Refugee Health. Evidence-based clinical guidelines for immigrants and refugees. CMAJ. 2011;183(12):E824–925.
24 Scheller NM, Svanström H, Pasternak B, Arnheim-Dahlström L, Sundström K, Fink K, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313(1):54–61.
25 World Health Organisation. Global advisory committee on vaccine safety (GACVS). Safety update of HPV vaccines. Extract from report of GACVS meeting of 7-8 June 2017, published in the WHO. Wkly Epidemiol Rec. 2017;14:•••. Available at:
http://www.who.int/vaccine_safety/committee/topics/hpv/June_2017/en/.
26 Salis Gross C, Tatzel J, Lang P. Explorative Studie zur Akzeptanz des Impfens in impfkritischen Bevölkerungsgruppen der Schweiz. 2014;Available from:
http://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-i/nsi/etude-qualitative-snv.pdf.download.pdf/akzeptanz-impfen-schweiz.pdf
27 Office fédéral de la santé publique. La vaccination contre le HPV en Suisse : résultats d’une enquête nationale réalisée en 20142014. Bulletin OFSP. 2015;23:445–53.
28 Barrense-Dias Y, Akre C, Berchtold A, et al. Human Papillomavirus (HPV) Vaccine in Switzerland: The reasons why some young women do not get vaccinated. Abstract O12, Joint Annual Meeting of the Swiss Society of Paediatrics, Swiss Society of Paediatric Surgery and Swiss Society of Child and Adolescent Psychiatry and Psychotherapy, Lausanne (Switzerland), May 24/25, 2018. Frei zugänglich via
https://smw.ch/fileadmin/content/supplements/SMW_Suppl_228.pdf. Verifiziert am 30.8.2018
29 Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al.; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1–30.
30 Brotherton JM, Wrede CD. Offering HPV vaccination to women treated for high-grade cervical intra-epithelial neoplasia: what do you need to know? Aust N Z J Obstet Gynaecol. 2014;54(4):393–4.
31 Shulman LP. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. Yearbook of Obstetrics, Gynecology and Women’s Health. 2012;2012:296–8.
32 The President’s Cancer Panel. Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer. A Report to the President of the United States from the President’s Cancer Panel. Bethesda, MD: National Cancer Institut; 2014. Available from: https://deainfo.nci.nih.gov/advisory/pcp/annualreports/hpv/PDF/PCP Annual Report 2012-2013.pdf.
33 Yang Z, Cuzick J, Hunt WC, Wheeler CM. Concurrence of multiple human papillomavirus infections in a large US population-based cohort. Am J Epidemiol. 2014;180(11):1066–75.
34 Tota JE, Jiang M, Ramanakumar AV, Walter SD, Kaufman JS, Coutlée F, et al. Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination. PLoS One. 2016;11(12):e0166329.
35 Wymann MN, Zographos AS, Altpeter E, Spicher VM, Low N, Mäusezahl-Feuz M. Human papillomavirus vaccine uptake in adolescence and adherence to cervical cancer screening in Switzerland: a national cross-sectional survey. Int J Public Health. 2017;29(5):4238–10.
36 Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis. 2005;191(s1, Suppl 1):S97–106.
37 Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–59.
38 Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK. Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J Infect Dis. 2012;205(10):1544–53.
39 Cho C-Y, Lo Y-C, Hung M-C, Lai C-C, Chen C-J, Wu K-G. Risk of cancer in patients with genital warts: A nationwide, population-based cohort study in Taiwan. PLoS ONE 2017;12(8):e0183183.
40 Hartwig S, Guily JLS, Dominiak-Felden G, Alemany L, de Sanjose S. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infectious Agents and Cancer. 2017;12(1):19.
– Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241–68.
– Bosch FX, Robles C, Díaz M, Arbyn M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Oncology 2016 13:119–32.
– Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–59.
– Office fédéral de la santé publique (OFSP): matériel d’information, recommandations, réponses aux questions fréquentes sur la vaccination HPV:
https://www.bag.admin.ch/bag/fr/home/krankheiten/krankheiten-im-ueberblick/hpv.html